WASHINGTON, 4 Aug — RIA Novosti. anti-malarial drug hydroxychloroquine is not effective for the prevention of disease COVID-19 in asymptomatic patients, the authors of the study published in the New England Journal of Medicine on Wednesday.
In tests of the effectiveness of the drug online held at University of Minnesota, took part 821 resident of the United States and Canada. All participants tested had contact with sick COVID-19 without a means of personal protection, but had no symptoms of the disease.
In the study, 107 participants of the project was confirmed as a coronavirus new type, in this case, as the authors of the study, the drug had no significant effect on susceptibility to the disease: 49 cases in a period of five days took hydroxychloroquine, and 58 during the same period would be dummy medication.
meanwhile, scientists do not exclude that the drug may be more effective when used for patients with symptomatic COVID-19.
Antimalarial drug hydroxychloroquine is subject to a number of clinical studies, but fears of experts cause possible side effects from its use.
the American management on sanitary inspection behind quality of foodstuff and medicines (FDA) had previously said that the use of this drug for the treatment of coronavirus should be conducted strictly under the supervision of a physician. Despite this warning, the drug for the prevention of coronavirus was received by the President of the United States Donald trump after a number of cases COVID-19 among the White house staff.
who, in turn, temporarily suspended the tests of hydroxychloroquine against COVID-19 due reports of increased mortality among patients who were given the medicine, but on Wednesday announced the resumption of the study.
